- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00254553
A Study to Test a Measure of Symptoms of Older Men With Low Testosterone On and Off Testosterone Replacement Treatment (P05815)
December 11, 2015 updated by: Merck Sharp & Dohme LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two Period Cross Over Trial to Validate Patient-Reported Outcome Measures for Use in Men With Late Onset Hypogonadism
Hypogonadal males, particularly those whose condition manifested later in life, may experience common symptoms associated with their hypogonadism.
Questionnaires developed to assess these symptoms need to be tested.
The primary purpose of this study is to test or validate the Patient-Reported Symptom Measure, Androgen Deficiency Quality of Life Questionnaire and the Patient Global Impression Scale.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
Men with late-onset hypogonadism who are either on testosterone treatment or naïve of treatment:
- have symptoms of androgen deficiency at screening (after wash-out if applicable) i.e. with a positive score on the Androgen Deficiency in the Aging Male (ADAM) Questionnaire (a "yes" answer to questions 1 or 7 or any three other questions).
- morning total T levels of <=3 ng/mL (<=300 ng/dL; <=10.4 nmol/l) on two separate days prior to randomization (after appropriate wash-out, if applicable).
- calculated free T <=0.074 ng/mL.
- at least 50 and at most 75 years of age.
- BMI of at least 18 kg/m^2 or at most 32 kg/m^2
Inclusion Criteria for Normogonadal Men:
- morning total T levels <=3 ng/mL (<=300 ng/dL; <=10.4 nmol/L).
- calculated free T <=0.074 ng/mL.
- at least 50 and at most 75 years of age.
- BMI of at least 18 kg/m^2 or at most 32 kg/m^2
Exclusion Criteria:
- History or current diagnosis of prostate cancer or any clinically significant finding on prostate examination
- Severe obstructive symptoms of benign prostate hypertrophy
- Prostate specific antigen (PSA) levels greater than 4 ng/mL at screening
- History or current diagnosis of carcinoma of the breast
- Known chronic polycythemia and/or hematocrit greater than 50% at screening
- Treatment-naïve subjects with hyperprolactinemia at screening (serum prolactin level >=50 ng/mL)
- Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator
- clinically significant abnormal physical finding prior to randomization
- sensitive to trial medication or its components
- History or presence of hepatic or renal disorder considered as clinically relevant in the opinion of the investigator.
Exclusion Criteria for Normogonadal Men:
- Presence or previous diagnosis of androgen deficiency.
- Previous or present use of testosterone preparations
- Use of medication within the 12 weeks prior to the visit that may interfere with the objectives of the trial: hypothalamic/pituitary hormones and analogues (e.g., gonadotropins, ACTH, STH, Gn-RH agonists and antagonists, etc.); sex steroid
- Any other disease that in the opinion of the investigator might compromise or confound the subject's symptomatology (e.g., presence of clinically significant depression or other psychiatric disorders, unstable endocrine disorder, sleep apnea, cardiovascular and cerebrovascular diseases, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Arm 2
Placebo
|
two tubes of placebo per day
|
Active Comparator: Arm 1
Testim 1% (testosterone gel)
|
Testim_ 100 mg: two tubes of 50 mg of Testim_per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient -reported outcome measures
Time Frame: Baseline and after six weeks of treatment or placebo
|
Baseline and after six weeks of treatment or placebo
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2005
Primary Completion (Actual)
January 1, 2007
Study Completion (Actual)
January 1, 2007
Study Registration Dates
First Submitted
November 14, 2005
First Submitted That Met QC Criteria
November 14, 2005
First Posted (Estimate)
November 16, 2005
Study Record Updates
Last Update Posted (Estimate)
December 14, 2015
Last Update Submitted That Met QC Criteria
December 11, 2015
Last Verified
December 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
- P05815
- 169001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypogonadism
-
Rigshospitalet, DenmarkTerminatedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleDenmark
-
Shanghai Jiao Tong University School of MedicineUnknownIdiopathic Hypogonadotropic Hypogonadism
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
Clarus Therapeutics, Inc.CompletedMale Hypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.CompletedHypogonadotropic Hypogonadism | Primary HypogonadismUnited States
-
Endo PharmaceuticalsCompletedHypogonadism | Secondary Hypogonadism | Primary HypogonadismUnited States
-
Repros Therapeutics Inc.CompletedObesity | Acquired Hypogonadotropic HypogonadismUnited States
-
Massachusetts General HospitalRecruiting
-
Mereo BioPharmaCompleted
-
Organon and CoCompleted
Clinical Trials on Testim 1% (testosterone gel)
-
Stanford UniversityCompletedKidney Diseases | Kidney FailureUnited States
-
Boston Medical CenterNational Institute on Aging (NIA)TerminatedMuscular Diseases | Sarcopenia | HypogonadismUnited States
-
University of WashingtonNational Institutes of Health (NIH); National Institute on Aging (NIA)CompletedHealthyUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedContraception | HypogonadismUnited States
-
Biolab Sanus FarmaceuticaWithdrawnPost-menopausal Period
-
Endo PharmaceuticalsCompletedHypogonadotropic Hypogonadism | Hypogonadism | Hypogonadism, MaleUnited States
-
BioSante PharmaceuticalsCompletedHypoactive Sexual Desire DisorderUnited States, Canada
-
Mohit KheraTerminatedErectile Dysfunction | HypogonadismUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedContraceptionUnited States
-
Odense University HospitalUnknownMetabolic Syndrome | HypogonadismDenmark